Showing results (351-360 of 502) with videos related to
Sort By:
Pageof 51
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 23, 2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab eraNeal S McCall, Hamilton S McGinnis, James R Janopaul-Naylor, et al.The Journal of Biological Chemistry|January 5, 2012
Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinasesQi Qi, Kunyan He, Min-Heui Yoo, et al.Nature Communications|September 18, 2014
Small-molecule Bax agonists for cancer therapyMeiguo Xin, Rui Li, Maohua Xie, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2017
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I StudyKristin A Higgins, Rathi N Pillai, Zhengjia Chen, et al.Cancer|June 24, 2023
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancerNeal S McCall, James R Janopaul-Naylor, H Scott McGinnis, et al.Frontiers in Immunology|August 19, 2022
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung CancerDavid S Hong, Ajay K Gopal, Alexander N Shoushtari, et al.Cancer Research|August 29, 2024
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung CancerJunghui Koo, Chang-Soo Seong, Rebecca E Parker, et al.Current Problems in Cancer|May 8, 2026
Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancerAparna Sharma, Praful Pandey, Swasthik Upadhya, et al.Pageof 51